![]() ![]() Neurosarcoidosis associated with hypersomnolence treated with corticosteroids and brain irradiation. Rubinstein I, Gray TA, Moldofsky H, et al. Narcolepsy caused by acute disseminated encephalomyelitis. Gledhill RF, Bartel PR, Yoshida Y, et al. Narcolepsy associated with other central nervous system disorders. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Narcolepsy associated with lesions of the diencephalon. Transient cataplexy after removal of a craniopharyngioma. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Paroxysmal sleep as a presenting symptom of bilateral paramedian thalamic infarctions. Bjornstad B, Goodman SH, Sirven JI, et al. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Diagnostic ambiguities in a case of post-traumatic narcolepsy with cataplexy. Narcolepsy, head injury, and the problem of causality. Posttraumatic narcolepsy - two case reports and a mini review. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Narcolepsy and excessive daytime sleepiness. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Secondary narcolepsy in children with brain tumors. Marcus CL, Trescher WH, Halbower AC, et al. Philadelphia, PA: Elsevier Saunders 2005.Ħ. Principles and practice of sleep medicine. Sleep in children with neoplasms of the central nervous system: case review of 14 children. Philadelphia, PA: Lippincot Williams and Wilkins 2005.Ĥ. Washington, DC: American Psychiatric Publishing 2021.ģ. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). International classification of sleep disorders - third edition (ICSD-3). Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. European guideline and expert statements on the management of narcolepsy in adults and children. īassetti CLA, Kallweit U, Vignatelli L, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. Use of actigraphy for the evaluation of sleep disorders and circadian rhythm sleep-wake disorders: an American Academy of Sleep Medicine clinical practice guideline. calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybateħ5 mg orally once daily in the morning initially, increase to 150 mg once daily after at least 3 days according to response and tolerability, maximum 150 mg/dayġ50-250 mg orally once daily in the morningġ0-60 mg/day orally (immediate-release) given in 2-3 divided doses 10-60 mg/day (extended-release) given in 1-2 divided dosesĥ-60 mg/day orally (immediate-release) given in 1-3 divided doses 5-60 mg/day (extended-release) given in 1-2 divided dosesġ0-60 mg/day orally (immediate-release) given in 2-3 divided dosesĢ0 mg/day orally given in divided doses in the morning and at noon, maximum 60 mg/dayĪmerican Academy of Sleep Medicine.200 mg orally once daily in the morning initially, may increase to 400 mg/day given in divided doses in the morning and at noonĨ.9 mg orally once daily in the morning for 1 week, increase to 17.8 mg once daily for 1 week, then adjust dose according to response and tolerability, maximum 35.6 mg/day (17.8 mg/day in CYP2D6 poor metabolizers)Ĥ.5 to 9 g/day orally given at night in 2 divided doses ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |